nodes	percent_of_prediction	percent_of_DWPC	metapath
Paroxetine—CYP2B6—Tamoxifen—pancreatic cancer	0.0567	0.114	CbGbCtD
Paroxetine—CYP2B6—Irinotecan—pancreatic cancer	0.0436	0.0879	CbGbCtD
Paroxetine—CYP2C8—Tamoxifen—pancreatic cancer	0.043	0.0867	CbGbCtD
Paroxetine—CYP2C8—Erlotinib—pancreatic cancer	0.0365	0.0737	CbGbCtD
Paroxetine—CYP2C8—Fluorouracil—pancreatic cancer	0.0317	0.0639	CbGbCtD
Paroxetine—CYP2C9—Tamoxifen—pancreatic cancer	0.03	0.0605	CbGbCtD
Paroxetine—ABCB1—Tamoxifen—pancreatic cancer	0.0291	0.0587	CbGbCtD
Paroxetine—CYP2D6—Tamoxifen—pancreatic cancer	0.0274	0.0553	CbGbCtD
Paroxetine—ABCB1—Gemcitabine—pancreatic cancer	0.0251	0.0506	CbGbCtD
Paroxetine—ABCB1—Erlotinib—pancreatic cancer	0.0247	0.0499	CbGbCtD
Paroxetine—CYP2B6—Doxorubicin—pancreatic cancer	0.0238	0.048	CbGbCtD
Paroxetine—CYP2D6—Erlotinib—pancreatic cancer	0.0233	0.047	CbGbCtD
Paroxetine—ABCB1—Irinotecan—pancreatic cancer	0.0223	0.0451	CbGbCtD
Paroxetine—CYP2C9—Fluorouracil—pancreatic cancer	0.0221	0.0446	CbGbCtD
Paroxetine—ABCB1—Docetaxel—pancreatic cancer	0.0164	0.033	CbGbCtD
Paroxetine—ABCB1—Sunitinib—pancreatic cancer	0.0163	0.0329	CbGbCtD
Paroxetine—ABCB1—Doxorubicin—pancreatic cancer	0.0122	0.0246	CbGbCtD
Paroxetine—CYP2D6—Doxorubicin—pancreatic cancer	0.0115	0.0232	CbGbCtD
Paroxetine—Anaphylactic shock—Docetaxel—pancreatic cancer	9.34e-05	0.000265	CcSEcCtD
Paroxetine—Oedema—Docetaxel—pancreatic cancer	9.34e-05	0.000265	CcSEcCtD
Paroxetine—Weight increased—Doxorubicin—pancreatic cancer	9.33e-05	0.000264	CcSEcCtD
Paroxetine—Epistaxis—Epirubicin—pancreatic cancer	9.32e-05	0.000264	CcSEcCtD
Paroxetine—Pruritus—Gemcitabine—pancreatic cancer	9.32e-05	0.000264	CcSEcCtD
Paroxetine—Infection—Docetaxel—pancreatic cancer	9.28e-05	0.000263	CcSEcCtD
Paroxetine—Weight decreased—Doxorubicin—pancreatic cancer	9.28e-05	0.000263	CcSEcCtD
Paroxetine—Sinusitis—Epirubicin—pancreatic cancer	9.27e-05	0.000263	CcSEcCtD
Paroxetine—Hyperglycaemia—Doxorubicin—pancreatic cancer	9.25e-05	0.000262	CcSEcCtD
Paroxetine—Diarrhoea—Irinotecan—pancreatic cancer	9.25e-05	0.000262	CcSEcCtD
Paroxetine—Agranulocytosis—Epirubicin—pancreatic cancer	9.22e-05	0.000261	CcSEcCtD
Paroxetine—Pneumonia—Doxorubicin—pancreatic cancer	9.2e-05	0.000261	CcSEcCtD
Paroxetine—Shock—Docetaxel—pancreatic cancer	9.19e-05	0.00026	CcSEcCtD
Paroxetine—Nervous system disorder—Docetaxel—pancreatic cancer	9.16e-05	0.00026	CcSEcCtD
Paroxetine—Pruritus—Fluorouracil—pancreatic cancer	9.16e-05	0.000259	CcSEcCtD
Paroxetine—Thrombocytopenia—Docetaxel—pancreatic cancer	9.15e-05	0.000259	CcSEcCtD
Paroxetine—Drowsiness—Doxorubicin—pancreatic cancer	9.14e-05	0.000259	CcSEcCtD
Paroxetine—Tachycardia—Docetaxel—pancreatic cancer	9.12e-05	0.000258	CcSEcCtD
Paroxetine—Skin disorder—Docetaxel—pancreatic cancer	9.08e-05	0.000257	CcSEcCtD
Paroxetine—Stevens-Johnson syndrome—Doxorubicin—pancreatic cancer	9.07e-05	0.000257	CcSEcCtD
Paroxetine—Bradycardia—Epirubicin—pancreatic cancer	9.03e-05	0.000256	CcSEcCtD
Paroxetine—Diarrhoea—Gemcitabine—pancreatic cancer	9.01e-05	0.000255	CcSEcCtD
Paroxetine—Neuropathy peripheral—Doxorubicin—pancreatic cancer	8.96e-05	0.000254	CcSEcCtD
Paroxetine—Dizziness—Irinotecan—pancreatic cancer	8.94e-05	0.000253	CcSEcCtD
Paroxetine—Haemoglobin—Epirubicin—pancreatic cancer	8.92e-05	0.000253	CcSEcCtD
Paroxetine—Stomatitis—Doxorubicin—pancreatic cancer	8.91e-05	0.000252	CcSEcCtD
Paroxetine—Jaundice—Doxorubicin—pancreatic cancer	8.91e-05	0.000252	CcSEcCtD
Paroxetine—Rhinitis—Epirubicin—pancreatic cancer	8.89e-05	0.000252	CcSEcCtD
Paroxetine—Urinary tract infection—Doxorubicin—pancreatic cancer	8.89e-05	0.000252	CcSEcCtD
Paroxetine—Conjunctivitis—Doxorubicin—pancreatic cancer	8.89e-05	0.000252	CcSEcCtD
Paroxetine—Haemorrhage—Epirubicin—pancreatic cancer	8.87e-05	0.000251	CcSEcCtD
Paroxetine—Hepatitis—Epirubicin—pancreatic cancer	8.87e-05	0.000251	CcSEcCtD
Paroxetine—Diarrhoea—Fluorouracil—pancreatic cancer	8.86e-05	0.000251	CcSEcCtD
Paroxetine—Hypoaesthesia—Epirubicin—pancreatic cancer	8.83e-05	0.00025	CcSEcCtD
Paroxetine—Pharyngitis—Epirubicin—pancreatic cancer	8.8e-05	0.000249	CcSEcCtD
Paroxetine—Sweating—Doxorubicin—pancreatic cancer	8.77e-05	0.000248	CcSEcCtD
Paroxetine—Oedema peripheral—Epirubicin—pancreatic cancer	8.74e-05	0.000248	CcSEcCtD
Paroxetine—Hypotension—Docetaxel—pancreatic cancer	8.73e-05	0.000247	CcSEcCtD
Paroxetine—Haematuria—Doxorubicin—pancreatic cancer	8.72e-05	0.000247	CcSEcCtD
Paroxetine—Connective tissue disorder—Epirubicin—pancreatic cancer	8.72e-05	0.000247	CcSEcCtD
Paroxetine—Hepatobiliary disease—Doxorubicin—pancreatic cancer	8.65e-05	0.000245	CcSEcCtD
Paroxetine—Epistaxis—Doxorubicin—pancreatic cancer	8.62e-05	0.000244	CcSEcCtD
Paroxetine—Vomiting—Irinotecan—pancreatic cancer	8.59e-05	0.000243	CcSEcCtD
Paroxetine—Sinusitis—Doxorubicin—pancreatic cancer	8.58e-05	0.000243	CcSEcCtD
Paroxetine—Dizziness—Fluorouracil—pancreatic cancer	8.56e-05	0.000243	CcSEcCtD
Paroxetine—Visual impairment—Epirubicin—pancreatic cancer	8.55e-05	0.000242	CcSEcCtD
Paroxetine—Agranulocytosis—Doxorubicin—pancreatic cancer	8.53e-05	0.000242	CcSEcCtD
Paroxetine—Rash—Irinotecan—pancreatic cancer	8.52e-05	0.000241	CcSEcCtD
Paroxetine—Dermatitis—Irinotecan—pancreatic cancer	8.52e-05	0.000241	CcSEcCtD
Paroxetine—Musculoskeletal discomfort—Docetaxel—pancreatic cancer	8.51e-05	0.000241	CcSEcCtD
Paroxetine—Headache—Irinotecan—pancreatic cancer	8.47e-05	0.00024	CcSEcCtD
Paroxetine—Insomnia—Docetaxel—pancreatic cancer	8.45e-05	0.000239	CcSEcCtD
Paroxetine—Paraesthesia—Docetaxel—pancreatic cancer	8.39e-05	0.000238	CcSEcCtD
Paroxetine—Erythema multiforme—Epirubicin—pancreatic cancer	8.39e-05	0.000238	CcSEcCtD
Paroxetine—Vomiting—Gemcitabine—pancreatic cancer	8.37e-05	0.000237	CcSEcCtD
Paroxetine—Bradycardia—Doxorubicin—pancreatic cancer	8.36e-05	0.000237	CcSEcCtD
Paroxetine—Dyspnoea—Docetaxel—pancreatic cancer	8.33e-05	0.000236	CcSEcCtD
Paroxetine—Somnolence—Docetaxel—pancreatic cancer	8.31e-05	0.000235	CcSEcCtD
Paroxetine—Rash—Gemcitabine—pancreatic cancer	8.3e-05	0.000235	CcSEcCtD
Paroxetine—Dermatitis—Gemcitabine—pancreatic cancer	8.29e-05	0.000235	CcSEcCtD
Paroxetine—Eye disorder—Epirubicin—pancreatic cancer	8.29e-05	0.000235	CcSEcCtD
Paroxetine—Tinnitus—Epirubicin—pancreatic cancer	8.27e-05	0.000234	CcSEcCtD
Paroxetine—Haemoglobin—Doxorubicin—pancreatic cancer	8.25e-05	0.000234	CcSEcCtD
Paroxetine—Headache—Gemcitabine—pancreatic cancer	8.25e-05	0.000234	CcSEcCtD
Paroxetine—Cardiac disorder—Epirubicin—pancreatic cancer	8.23e-05	0.000233	CcSEcCtD
Paroxetine—Flushing—Epirubicin—pancreatic cancer	8.23e-05	0.000233	CcSEcCtD
Paroxetine—Vomiting—Fluorouracil—pancreatic cancer	8.23e-05	0.000233	CcSEcCtD
Paroxetine—Rhinitis—Doxorubicin—pancreatic cancer	8.23e-05	0.000233	CcSEcCtD
Paroxetine—Dyspepsia—Docetaxel—pancreatic cancer	8.23e-05	0.000233	CcSEcCtD
Paroxetine—Haemorrhage—Doxorubicin—pancreatic cancer	8.21e-05	0.000233	CcSEcCtD
Paroxetine—Hepatitis—Doxorubicin—pancreatic cancer	8.21e-05	0.000233	CcSEcCtD
Paroxetine—Hypoaesthesia—Doxorubicin—pancreatic cancer	8.17e-05	0.000231	CcSEcCtD
Paroxetine—Rash—Fluorouracil—pancreatic cancer	8.16e-05	0.000231	CcSEcCtD
Paroxetine—Dermatitis—Fluorouracil—pancreatic cancer	8.16e-05	0.000231	CcSEcCtD
Paroxetine—Pharyngitis—Doxorubicin—pancreatic cancer	8.15e-05	0.000231	CcSEcCtD
Paroxetine—Decreased appetite—Docetaxel—pancreatic cancer	8.12e-05	0.00023	CcSEcCtD
Paroxetine—Headache—Fluorouracil—pancreatic cancer	8.11e-05	0.00023	CcSEcCtD
Paroxetine—Oedema peripheral—Doxorubicin—pancreatic cancer	8.09e-05	0.000229	CcSEcCtD
Paroxetine—Gastrointestinal disorder—Docetaxel—pancreatic cancer	8.07e-05	0.000229	CcSEcCtD
Paroxetine—Connective tissue disorder—Doxorubicin—pancreatic cancer	8.07e-05	0.000228	CcSEcCtD
Paroxetine—Fatigue—Docetaxel—pancreatic cancer	8.06e-05	0.000228	CcSEcCtD
Paroxetine—Angiopathy—Epirubicin—pancreatic cancer	8.05e-05	0.000228	CcSEcCtD
Paroxetine—Nausea—Irinotecan—pancreatic cancer	8.03e-05	0.000227	CcSEcCtD
Paroxetine—Immune system disorder—Epirubicin—pancreatic cancer	8.01e-05	0.000227	CcSEcCtD
Paroxetine—Mediastinal disorder—Epirubicin—pancreatic cancer	8e-05	0.000226	CcSEcCtD
Paroxetine—Pain—Docetaxel—pancreatic cancer	7.99e-05	0.000226	CcSEcCtD
Paroxetine—Constipation—Docetaxel—pancreatic cancer	7.99e-05	0.000226	CcSEcCtD
Paroxetine—Chills—Epirubicin—pancreatic cancer	7.96e-05	0.000225	CcSEcCtD
Paroxetine—Arrhythmia—Epirubicin—pancreatic cancer	7.93e-05	0.000224	CcSEcCtD
Paroxetine—Visual impairment—Doxorubicin—pancreatic cancer	7.91e-05	0.000224	CcSEcCtD
Paroxetine—Alopecia—Epirubicin—pancreatic cancer	7.84e-05	0.000222	CcSEcCtD
Paroxetine—Nausea—Gemcitabine—pancreatic cancer	7.82e-05	0.000222	CcSEcCtD
Paroxetine—Mental disorder—Epirubicin—pancreatic cancer	7.77e-05	0.00022	CcSEcCtD
Paroxetine—Erythema multiforme—Doxorubicin—pancreatic cancer	7.76e-05	0.00022	CcSEcCtD
Paroxetine—Erythema—Epirubicin—pancreatic cancer	7.72e-05	0.000219	CcSEcCtD
Paroxetine—Malnutrition—Epirubicin—pancreatic cancer	7.72e-05	0.000219	CcSEcCtD
Paroxetine—Feeling abnormal—Docetaxel—pancreatic cancer	7.7e-05	0.000218	CcSEcCtD
Paroxetine—Nausea—Fluorouracil—pancreatic cancer	7.69e-05	0.000218	CcSEcCtD
Paroxetine—Eye disorder—Doxorubicin—pancreatic cancer	7.67e-05	0.000217	CcSEcCtD
Paroxetine—Tinnitus—Doxorubicin—pancreatic cancer	7.65e-05	0.000217	CcSEcCtD
Paroxetine—Gastrointestinal pain—Docetaxel—pancreatic cancer	7.64e-05	0.000216	CcSEcCtD
Paroxetine—Cardiac disorder—Doxorubicin—pancreatic cancer	7.62e-05	0.000216	CcSEcCtD
Paroxetine—Flushing—Doxorubicin—pancreatic cancer	7.62e-05	0.000216	CcSEcCtD
Paroxetine—Flatulence—Epirubicin—pancreatic cancer	7.61e-05	0.000216	CcSEcCtD
Paroxetine—Tension—Epirubicin—pancreatic cancer	7.58e-05	0.000215	CcSEcCtD
Paroxetine—Dysgeusia—Epirubicin—pancreatic cancer	7.56e-05	0.000214	CcSEcCtD
Paroxetine—Nervousness—Epirubicin—pancreatic cancer	7.5e-05	0.000212	CcSEcCtD
Paroxetine—Back pain—Epirubicin—pancreatic cancer	7.47e-05	0.000212	CcSEcCtD
Paroxetine—Angiopathy—Doxorubicin—pancreatic cancer	7.45e-05	0.000211	CcSEcCtD
Paroxetine—Muscle spasms—Epirubicin—pancreatic cancer	7.42e-05	0.00021	CcSEcCtD
Paroxetine—Immune system disorder—Doxorubicin—pancreatic cancer	7.41e-05	0.00021	CcSEcCtD
Paroxetine—Mediastinal disorder—Doxorubicin—pancreatic cancer	7.4e-05	0.00021	CcSEcCtD
Paroxetine—Abdominal pain—Docetaxel—pancreatic cancer	7.39e-05	0.000209	CcSEcCtD
Paroxetine—Body temperature increased—Docetaxel—pancreatic cancer	7.39e-05	0.000209	CcSEcCtD
Paroxetine—Chills—Doxorubicin—pancreatic cancer	7.37e-05	0.000209	CcSEcCtD
Paroxetine—Arrhythmia—Doxorubicin—pancreatic cancer	7.33e-05	0.000208	CcSEcCtD
Paroxetine—Vision blurred—Epirubicin—pancreatic cancer	7.28e-05	0.000206	CcSEcCtD
Paroxetine—Alopecia—Doxorubicin—pancreatic cancer	7.25e-05	0.000205	CcSEcCtD
Paroxetine—Mental disorder—Doxorubicin—pancreatic cancer	7.19e-05	0.000204	CcSEcCtD
Paroxetine—Ill-defined disorder—Epirubicin—pancreatic cancer	7.17e-05	0.000203	CcSEcCtD
Paroxetine—Erythema—Doxorubicin—pancreatic cancer	7.15e-05	0.000202	CcSEcCtD
Paroxetine—Malnutrition—Doxorubicin—pancreatic cancer	7.15e-05	0.000202	CcSEcCtD
Paroxetine—Anaemia—Epirubicin—pancreatic cancer	7.14e-05	0.000202	CcSEcCtD
Paroxetine—Agitation—Epirubicin—pancreatic cancer	7.1e-05	0.000201	CcSEcCtD
Paroxetine—Flatulence—Doxorubicin—pancreatic cancer	7.04e-05	0.000199	CcSEcCtD
Paroxetine—Tension—Doxorubicin—pancreatic cancer	7.01e-05	0.000199	CcSEcCtD
Paroxetine—Dysgeusia—Doxorubicin—pancreatic cancer	7e-05	0.000198	CcSEcCtD
Paroxetine—Malaise—Epirubicin—pancreatic cancer	6.96e-05	0.000197	CcSEcCtD
Paroxetine—Nervousness—Doxorubicin—pancreatic cancer	6.94e-05	0.000197	CcSEcCtD
Paroxetine—Vertigo—Epirubicin—pancreatic cancer	6.94e-05	0.000197	CcSEcCtD
Paroxetine—Syncope—Epirubicin—pancreatic cancer	6.93e-05	0.000196	CcSEcCtD
Paroxetine—Leukopenia—Epirubicin—pancreatic cancer	6.91e-05	0.000196	CcSEcCtD
Paroxetine—Back pain—Doxorubicin—pancreatic cancer	6.91e-05	0.000196	CcSEcCtD
Paroxetine—Hypersensitivity—Docetaxel—pancreatic cancer	6.88e-05	0.000195	CcSEcCtD
Paroxetine—Muscle spasms—Doxorubicin—pancreatic cancer	6.87e-05	0.000195	CcSEcCtD
Paroxetine—Palpitations—Epirubicin—pancreatic cancer	6.82e-05	0.000193	CcSEcCtD
Paroxetine—Loss of consciousness—Epirubicin—pancreatic cancer	6.79e-05	0.000192	CcSEcCtD
Paroxetine—Cough—Epirubicin—pancreatic cancer	6.74e-05	0.000191	CcSEcCtD
Paroxetine—Vision blurred—Doxorubicin—pancreatic cancer	6.73e-05	0.000191	CcSEcCtD
Paroxetine—Asthenia—Docetaxel—pancreatic cancer	6.7e-05	0.00019	CcSEcCtD
Paroxetine—Convulsion—Epirubicin—pancreatic cancer	6.69e-05	0.00019	CcSEcCtD
Paroxetine—Hypertension—Epirubicin—pancreatic cancer	6.67e-05	0.000189	CcSEcCtD
Paroxetine—Ill-defined disorder—Doxorubicin—pancreatic cancer	6.63e-05	0.000188	CcSEcCtD
Paroxetine—Pruritus—Docetaxel—pancreatic cancer	6.61e-05	0.000187	CcSEcCtD
Paroxetine—Anaemia—Doxorubicin—pancreatic cancer	6.6e-05	0.000187	CcSEcCtD
Paroxetine—Myalgia—Epirubicin—pancreatic cancer	6.57e-05	0.000186	CcSEcCtD
Paroxetine—Arthralgia—Epirubicin—pancreatic cancer	6.57e-05	0.000186	CcSEcCtD
Paroxetine—Chest pain—Epirubicin—pancreatic cancer	6.57e-05	0.000186	CcSEcCtD
Paroxetine—Agitation—Doxorubicin—pancreatic cancer	6.57e-05	0.000186	CcSEcCtD
Paroxetine—Anxiety—Epirubicin—pancreatic cancer	6.55e-05	0.000186	CcSEcCtD
Paroxetine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—pancreatic cancer	6.53e-05	0.000185	CcSEcCtD
Paroxetine—Discomfort—Epirubicin—pancreatic cancer	6.5e-05	0.000184	CcSEcCtD
Paroxetine—Malaise—Doxorubicin—pancreatic cancer	6.44e-05	0.000183	CcSEcCtD
Paroxetine—Dry mouth—Epirubicin—pancreatic cancer	6.43e-05	0.000182	CcSEcCtD
Paroxetine—Vertigo—Doxorubicin—pancreatic cancer	6.42e-05	0.000182	CcSEcCtD
Paroxetine—Syncope—Doxorubicin—pancreatic cancer	6.41e-05	0.000182	CcSEcCtD
Paroxetine—Leukopenia—Doxorubicin—pancreatic cancer	6.4e-05	0.000181	CcSEcCtD
Paroxetine—Diarrhoea—Docetaxel—pancreatic cancer	6.39e-05	0.000181	CcSEcCtD
Paroxetine—Confusional state—Epirubicin—pancreatic cancer	6.36e-05	0.00018	CcSEcCtD
Paroxetine—Palpitations—Doxorubicin—pancreatic cancer	6.31e-05	0.000179	CcSEcCtD
Paroxetine—Anaphylactic shock—Epirubicin—pancreatic cancer	6.3e-05	0.000179	CcSEcCtD
Paroxetine—Oedema—Epirubicin—pancreatic cancer	6.3e-05	0.000179	CcSEcCtD
Paroxetine—Loss of consciousness—Doxorubicin—pancreatic cancer	6.28e-05	0.000178	CcSEcCtD
Paroxetine—Infection—Epirubicin—pancreatic cancer	6.26e-05	0.000177	CcSEcCtD
Paroxetine—Cough—Doxorubicin—pancreatic cancer	6.24e-05	0.000177	CcSEcCtD
Paroxetine—Shock—Epirubicin—pancreatic cancer	6.2e-05	0.000176	CcSEcCtD
Paroxetine—Convulsion—Doxorubicin—pancreatic cancer	6.19e-05	0.000175	CcSEcCtD
Paroxetine—Nervous system disorder—Epirubicin—pancreatic cancer	6.18e-05	0.000175	CcSEcCtD
Paroxetine—Dizziness—Docetaxel—pancreatic cancer	6.18e-05	0.000175	CcSEcCtD
Paroxetine—Thrombocytopenia—Epirubicin—pancreatic cancer	6.17e-05	0.000175	CcSEcCtD
Paroxetine—Hypertension—Doxorubicin—pancreatic cancer	6.17e-05	0.000175	CcSEcCtD
Paroxetine—Tachycardia—Epirubicin—pancreatic cancer	6.15e-05	0.000174	CcSEcCtD
Paroxetine—Skin disorder—Epirubicin—pancreatic cancer	6.12e-05	0.000173	CcSEcCtD
Paroxetine—Hyperhidrosis—Epirubicin—pancreatic cancer	6.09e-05	0.000173	CcSEcCtD
Paroxetine—Chest pain—Doxorubicin—pancreatic cancer	6.08e-05	0.000172	CcSEcCtD
Paroxetine—Arthralgia—Doxorubicin—pancreatic cancer	6.08e-05	0.000172	CcSEcCtD
Paroxetine—Myalgia—Doxorubicin—pancreatic cancer	6.08e-05	0.000172	CcSEcCtD
Paroxetine—Anxiety—Doxorubicin—pancreatic cancer	6.06e-05	0.000172	CcSEcCtD
Paroxetine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—pancreatic cancer	6.04e-05	0.000171	CcSEcCtD
Paroxetine—Discomfort—Doxorubicin—pancreatic cancer	6.01e-05	0.00017	CcSEcCtD
Paroxetine—Dry mouth—Doxorubicin—pancreatic cancer	5.95e-05	0.000169	CcSEcCtD
Paroxetine—Vomiting—Docetaxel—pancreatic cancer	5.94e-05	0.000168	CcSEcCtD
Paroxetine—Rash—Docetaxel—pancreatic cancer	5.89e-05	0.000167	CcSEcCtD
Paroxetine—Hypotension—Epirubicin—pancreatic cancer	5.89e-05	0.000167	CcSEcCtD
Paroxetine—Dermatitis—Docetaxel—pancreatic cancer	5.89e-05	0.000167	CcSEcCtD
Paroxetine—Confusional state—Doxorubicin—pancreatic cancer	5.88e-05	0.000167	CcSEcCtD
Paroxetine—Headache—Docetaxel—pancreatic cancer	5.85e-05	0.000166	CcSEcCtD
Paroxetine—Anaphylactic shock—Doxorubicin—pancreatic cancer	5.83e-05	0.000165	CcSEcCtD
Paroxetine—Oedema—Doxorubicin—pancreatic cancer	5.83e-05	0.000165	CcSEcCtD
Paroxetine—Infection—Doxorubicin—pancreatic cancer	5.79e-05	0.000164	CcSEcCtD
Paroxetine—Musculoskeletal discomfort—Epirubicin—pancreatic cancer	5.74e-05	0.000163	CcSEcCtD
Paroxetine—Shock—Doxorubicin—pancreatic cancer	5.74e-05	0.000163	CcSEcCtD
Paroxetine—Nervous system disorder—Doxorubicin—pancreatic cancer	5.72e-05	0.000162	CcSEcCtD
Paroxetine—Thrombocytopenia—Doxorubicin—pancreatic cancer	5.71e-05	0.000162	CcSEcCtD
Paroxetine—Insomnia—Epirubicin—pancreatic cancer	5.7e-05	0.000161	CcSEcCtD
Paroxetine—Tachycardia—Doxorubicin—pancreatic cancer	5.69e-05	0.000161	CcSEcCtD
Paroxetine—Skin disorder—Doxorubicin—pancreatic cancer	5.66e-05	0.00016	CcSEcCtD
Paroxetine—Paraesthesia—Epirubicin—pancreatic cancer	5.66e-05	0.00016	CcSEcCtD
Paroxetine—Hyperhidrosis—Doxorubicin—pancreatic cancer	5.64e-05	0.00016	CcSEcCtD
Paroxetine—Dyspnoea—Epirubicin—pancreatic cancer	5.62e-05	0.000159	CcSEcCtD
Paroxetine—Somnolence—Epirubicin—pancreatic cancer	5.6e-05	0.000159	CcSEcCtD
Paroxetine—Nausea—Docetaxel—pancreatic cancer	5.55e-05	0.000157	CcSEcCtD
Paroxetine—Dyspepsia—Epirubicin—pancreatic cancer	5.55e-05	0.000157	CcSEcCtD
Paroxetine—Decreased appetite—Epirubicin—pancreatic cancer	5.48e-05	0.000155	CcSEcCtD
Paroxetine—Hypotension—Doxorubicin—pancreatic cancer	5.45e-05	0.000154	CcSEcCtD
Paroxetine—Gastrointestinal disorder—Epirubicin—pancreatic cancer	5.44e-05	0.000154	CcSEcCtD
Paroxetine—Fatigue—Epirubicin—pancreatic cancer	5.43e-05	0.000154	CcSEcCtD
Paroxetine—Pain—Epirubicin—pancreatic cancer	5.39e-05	0.000153	CcSEcCtD
Paroxetine—Constipation—Epirubicin—pancreatic cancer	5.39e-05	0.000153	CcSEcCtD
Paroxetine—Musculoskeletal discomfort—Doxorubicin—pancreatic cancer	5.31e-05	0.000151	CcSEcCtD
Paroxetine—Insomnia—Doxorubicin—pancreatic cancer	5.27e-05	0.000149	CcSEcCtD
Paroxetine—Paraesthesia—Doxorubicin—pancreatic cancer	5.24e-05	0.000148	CcSEcCtD
Paroxetine—Dyspnoea—Doxorubicin—pancreatic cancer	5.2e-05	0.000147	CcSEcCtD
Paroxetine—Feeling abnormal—Epirubicin—pancreatic cancer	5.19e-05	0.000147	CcSEcCtD
Paroxetine—Somnolence—Doxorubicin—pancreatic cancer	5.18e-05	0.000147	CcSEcCtD
Paroxetine—Gastrointestinal pain—Epirubicin—pancreatic cancer	5.15e-05	0.000146	CcSEcCtD
Paroxetine—Dyspepsia—Doxorubicin—pancreatic cancer	5.13e-05	0.000145	CcSEcCtD
Paroxetine—Decreased appetite—Doxorubicin—pancreatic cancer	5.07e-05	0.000144	CcSEcCtD
Paroxetine—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	5.03e-05	0.000143	CcSEcCtD
Paroxetine—Fatigue—Doxorubicin—pancreatic cancer	5.03e-05	0.000142	CcSEcCtD
Paroxetine—Urticaria—Epirubicin—pancreatic cancer	5.01e-05	0.000142	CcSEcCtD
Paroxetine—Pain—Doxorubicin—pancreatic cancer	4.99e-05	0.000141	CcSEcCtD
Paroxetine—Constipation—Doxorubicin—pancreatic cancer	4.99e-05	0.000141	CcSEcCtD
Paroxetine—Abdominal pain—Epirubicin—pancreatic cancer	4.98e-05	0.000141	CcSEcCtD
Paroxetine—Body temperature increased—Epirubicin—pancreatic cancer	4.98e-05	0.000141	CcSEcCtD
Paroxetine—Feeling abnormal—Doxorubicin—pancreatic cancer	4.81e-05	0.000136	CcSEcCtD
Paroxetine—Gastrointestinal pain—Doxorubicin—pancreatic cancer	4.77e-05	0.000135	CcSEcCtD
Paroxetine—Hypersensitivity—Epirubicin—pancreatic cancer	4.64e-05	0.000132	CcSEcCtD
Paroxetine—Urticaria—Doxorubicin—pancreatic cancer	4.63e-05	0.000131	CcSEcCtD
Paroxetine—Abdominal pain—Doxorubicin—pancreatic cancer	4.61e-05	0.000131	CcSEcCtD
Paroxetine—Body temperature increased—Doxorubicin—pancreatic cancer	4.61e-05	0.000131	CcSEcCtD
Paroxetine—Asthenia—Epirubicin—pancreatic cancer	4.52e-05	0.000128	CcSEcCtD
Paroxetine—Pruritus—Epirubicin—pancreatic cancer	4.46e-05	0.000126	CcSEcCtD
Paroxetine—Diarrhoea—Epirubicin—pancreatic cancer	4.31e-05	0.000122	CcSEcCtD
Paroxetine—Hypersensitivity—Doxorubicin—pancreatic cancer	4.3e-05	0.000122	CcSEcCtD
Paroxetine—Asthenia—Doxorubicin—pancreatic cancer	4.18e-05	0.000119	CcSEcCtD
Paroxetine—Dizziness—Epirubicin—pancreatic cancer	4.17e-05	0.000118	CcSEcCtD
Paroxetine—Pruritus—Doxorubicin—pancreatic cancer	4.13e-05	0.000117	CcSEcCtD
Paroxetine—Vomiting—Epirubicin—pancreatic cancer	4.01e-05	0.000114	CcSEcCtD
Paroxetine—Diarrhoea—Doxorubicin—pancreatic cancer	3.99e-05	0.000113	CcSEcCtD
Paroxetine—Rash—Epirubicin—pancreatic cancer	3.97e-05	0.000113	CcSEcCtD
Paroxetine—Dermatitis—Epirubicin—pancreatic cancer	3.97e-05	0.000112	CcSEcCtD
Paroxetine—Headache—Epirubicin—pancreatic cancer	3.95e-05	0.000112	CcSEcCtD
Paroxetine—Dizziness—Doxorubicin—pancreatic cancer	3.86e-05	0.000109	CcSEcCtD
Paroxetine—Nausea—Epirubicin—pancreatic cancer	3.74e-05	0.000106	CcSEcCtD
Paroxetine—Vomiting—Doxorubicin—pancreatic cancer	3.71e-05	0.000105	CcSEcCtD
Paroxetine—Rash—Doxorubicin—pancreatic cancer	3.68e-05	0.000104	CcSEcCtD
Paroxetine—Dermatitis—Doxorubicin—pancreatic cancer	3.67e-05	0.000104	CcSEcCtD
Paroxetine—Headache—Doxorubicin—pancreatic cancer	3.65e-05	0.000103	CcSEcCtD
Paroxetine—Nausea—Doxorubicin—pancreatic cancer	3.46e-05	9.81e-05	CcSEcCtD
Paroxetine—CHRM2—Signaling Pathways—TERT—pancreatic cancer	1.13e-05	7.47e-05	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—PPARG—pancreatic cancer	1.11e-05	7.34e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—HIF1A—pancreatic cancer	1.1e-05	7.28e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—TSC2—pancreatic cancer	1.1e-05	7.26e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—PIK3CB—pancreatic cancer	1.1e-05	7.25e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—APOE—pancreatic cancer	1.1e-05	7.25e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—HIF1A—pancreatic cancer	1.1e-05	7.24e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—TSC2—pancreatic cancer	1.09e-05	7.22e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—HIF1A—pancreatic cancer	1.09e-05	7.22e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—STK11—pancreatic cancer	1.09e-05	7.2e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—TSC2—pancreatic cancer	1.09e-05	7.2e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—PIK3CA—pancreatic cancer	1.08e-05	7.16e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—HIF1A—pancreatic cancer	1.08e-05	7.15e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—STK11—pancreatic cancer	1.08e-05	7.14e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—TSC2—pancreatic cancer	1.08e-05	7.13e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—APOE—pancreatic cancer	1.08e-05	7.1e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—APOE—pancreatic cancer	1.07e-05	7.07e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—APOE—pancreatic cancer	1.07e-05	7.04e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—APOE—pancreatic cancer	1.06e-05	6.98e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—CXCL8—pancreatic cancer	1.05e-05	6.96e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—KDR—pancreatic cancer	1.05e-05	6.96e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—PIK3CB—pancreatic cancer	1.05e-05	6.94e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—KDR—pancreatic cancer	1.05e-05	6.92e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—HRAS—pancreatic cancer	1.05e-05	6.92e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—KDR—pancreatic cancer	1.04e-05	6.9e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—KDR—pancreatic cancer	1.03e-05	6.83e-05	CbGpPWpGaD
Paroxetine—CHRM4—GPCR downstream signaling—AKT1—pancreatic cancer	1.02e-05	6.73e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	1.01e-05	6.7e-05	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—PIK3CD—pancreatic cancer	1.01e-05	6.68e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—CXCL8—pancreatic cancer	1.01e-05	6.67e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—CASP3—pancreatic cancer	1.01e-05	6.67e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—HRAS—pancreatic cancer	1e-05	6.63e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—NFKBIA—pancreatic cancer	1e-05	6.62e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—NFKBIA—pancreatic cancer	9.97e-06	6.58e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—TYMS—pancreatic cancer	9.95e-06	6.57e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—NFKBIA—pancreatic cancer	9.93e-06	6.56e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—NOTCH1—pancreatic cancer	9.92e-06	6.56e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—PIK3CG—pancreatic cancer	9.9e-06	6.54e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—NOTCH1—pancreatic cancer	9.87e-06	6.52e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—NOTCH1—pancreatic cancer	9.84e-06	6.5e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—NFKBIA—pancreatic cancer	9.84e-06	6.5e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—CCND1—pancreatic cancer	9.82e-06	6.49e-05	CbGpPWpGaD
Paroxetine—CHRM5—GPCR downstream signaling—AKT1—pancreatic cancer	9.75e-06	6.44e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—NOTCH1—pancreatic cancer	9.74e-06	6.44e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—CTNNB1—pancreatic cancer	9.72e-06	6.42e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—PIK3CG—pancreatic cancer	9.7e-06	6.41e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—NRAS—pancreatic cancer	9.7e-06	6.41e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—CASP3—pancreatic cancer	9.66e-06	6.38e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—PIK3CG—pancreatic cancer	9.65e-06	6.38e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—NRAS—pancreatic cancer	9.65e-06	6.38e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—PIK3CG—pancreatic cancer	9.62e-06	6.36e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—NRAS—pancreatic cancer	9.62e-06	6.36e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—EGF—pancreatic cancer	9.59e-06	6.34e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—PPARG—pancreatic cancer	9.55e-06	6.31e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—EGF—pancreatic cancer	9.54e-06	6.3e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—MMP9—pancreatic cancer	9.53e-06	6.3e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—PIK3CG—pancreatic cancer	9.53e-06	6.29e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—NRAS—pancreatic cancer	9.53e-06	6.29e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—EGF—pancreatic cancer	9.51e-06	6.28e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—PTEN—pancreatic cancer	9.48e-06	6.26e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—EGF—pancreatic cancer	9.42e-06	6.22e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—CCND1—pancreatic cancer	9.4e-06	6.21e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—TYMS—pancreatic cancer	9.37e-06	6.19e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—CTNNB1—pancreatic cancer	9.31e-06	6.15e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—TYMS—pancreatic cancer	9.29e-06	6.14e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—APOE—pancreatic cancer	9.29e-06	6.14e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—AKT1—pancreatic cancer	9.25e-06	6.11e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—MMP9—pancreatic cancer	9.13e-06	6.03e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—PTEN—pancreatic cancer	9.08e-06	6e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—AKT1—pancreatic cancer	8.85e-06	5.85e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—EGFR—pancreatic cancer	8.84e-06	5.84e-05	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—PIK3CB—pancreatic cancer	8.82e-06	5.83e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—EGFR—pancreatic cancer	8.79e-06	5.81e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	8.79e-06	5.81e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—SRC—pancreatic cancer	8.79e-06	5.81e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—EGFR—pancreatic cancer	8.77e-06	5.79e-05	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—PTGS2—pancreatic cancer	8.74e-06	5.77e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—PIK3CD—pancreatic cancer	8.7e-06	5.75e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—EGFR—pancreatic cancer	8.68e-06	5.74e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—VEGFA—pancreatic cancer	8.56e-06	5.66e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—PIK3CD—pancreatic cancer	8.53e-06	5.64e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—PIK3CD—pancreatic cancer	8.49e-06	5.61e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—STAT3—pancreatic cancer	8.48e-06	5.6e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—PIK3CD—pancreatic cancer	8.46e-06	5.59e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—NRAS—pancreatic cancer	8.46e-06	5.59e-05	CbGpPWpGaD
Paroxetine—HTR2A—GPCR downstream signaling—PIK3CA—pancreatic cancer	8.45e-06	5.58e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—SRC—pancreatic cancer	8.42e-06	5.56e-05	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—PIK3CA—pancreatic cancer	8.4e-06	5.55e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—PIK3CG—pancreatic cancer	8.38e-06	5.54e-05	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—PIK3CA—pancreatic cancer	8.38e-06	5.54e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—PIK3CD—pancreatic cancer	8.38e-06	5.53e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—KRAS—pancreatic cancer	8.35e-06	5.52e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—KRAS—pancreatic cancer	8.31e-06	5.49e-05	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—PIK3CA—pancreatic cancer	8.3e-06	5.48e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—KRAS—pancreatic cancer	8.28e-06	5.47e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—KRAS—pancreatic cancer	8.2e-06	5.42e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—VEGFA—pancreatic cancer	8.2e-06	5.42e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—STAT3—pancreatic cancer	8.12e-06	5.36e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—NRAS—pancreatic cancer	8.1e-06	5.35e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—APOE—pancreatic cancer	8.09e-06	5.34e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—PPARG—pancreatic cancer	8.09e-06	5.34e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—MYC—pancreatic cancer	7.88e-06	5.2e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—TGFB1—pancreatic cancer	7.86e-06	5.19e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—EGFR—pancreatic cancer	7.7e-06	5.09e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—PIK3CA—pancreatic cancer	7.67e-06	5.07e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—PIK3CA—pancreatic cancer	7.63e-06	5.04e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—APOE—pancreatic cancer	7.62e-06	5.04e-05	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—PTEN—pancreatic cancer	7.62e-06	5.03e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—PIK3CA—pancreatic cancer	7.61e-06	5.03e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—PIK3CB—pancreatic cancer	7.58e-06	5.01e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—APOE—pancreatic cancer	7.56e-06	4.99e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—MYC—pancreatic cancer	7.54e-06	4.98e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—PIK3CA—pancreatic cancer	7.53e-06	4.98e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—TGFB1—pancreatic cancer	7.52e-06	4.97e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—PTGS2—pancreatic cancer	7.52e-06	4.97e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—PIK3CB—pancreatic cancer	7.44e-06	4.91e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—PIK3CB—pancreatic cancer	7.4e-06	4.89e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—EGFR—pancreatic cancer	7.38e-06	4.87e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—PIK3CB—pancreatic cancer	7.37e-06	4.87e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—PIK3CD—pancreatic cancer	7.37e-06	4.87e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—PIK3CG—pancreatic cancer	7.3e-06	4.82e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—PIK3CB—pancreatic cancer	7.3e-06	4.82e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—KRAS—pancreatic cancer	7.28e-06	4.81e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	7.15e-06	4.73e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—CXCL8—pancreatic cancer	7.15e-06	4.72e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—CXCL8—pancreatic cancer	7.11e-06	4.7e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—HRAS—pancreatic cancer	7.1e-06	4.69e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—CXCL8—pancreatic cancer	7.08e-06	4.68e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—HRAS—pancreatic cancer	7.06e-06	4.67e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—PPARG—pancreatic cancer	7.05e-06	4.66e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—HRAS—pancreatic cancer	7.04e-06	4.65e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—CXCL8—pancreatic cancer	7.02e-06	4.64e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—HRAS—pancreatic cancer	6.97e-06	4.61e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—KRAS—pancreatic cancer	6.97e-06	4.6e-05	CbGpPWpGaD
Paroxetine—HTR2A—GPCR downstream signaling—AKT1—pancreatic cancer	6.9e-06	4.56e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—PIK3CG—pancreatic cancer	6.88e-06	4.55e-05	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—AKT1—pancreatic cancer	6.87e-06	4.54e-05	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—AKT1—pancreatic cancer	6.84e-06	4.52e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—CASP3—pancreatic cancer	6.84e-06	4.52e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—PIK3CG—pancreatic cancer	6.82e-06	4.51e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—CASP3—pancreatic cancer	6.8e-06	4.49e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—CASP3—pancreatic cancer	6.78e-06	4.48e-05	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—AKT1—pancreatic cancer	6.78e-06	4.48e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—CASP3—pancreatic cancer	6.71e-06	4.44e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—PIK3CA—pancreatic cancer	6.69e-06	4.42e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—CCND1—pancreatic cancer	6.66e-06	4.4e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—PPARG—pancreatic cancer	6.64e-06	4.39e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—CCND1—pancreatic cancer	6.62e-06	4.37e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—CCND1—pancreatic cancer	6.6e-06	4.36e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—CTNNB1—pancreatic cancer	6.59e-06	4.36e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—PPARG—pancreatic cancer	6.58e-06	4.35e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—CTNNB1—pancreatic cancer	6.56e-06	4.33e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—PTEN—pancreatic cancer	6.55e-06	4.33e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—CCND1—pancreatic cancer	6.54e-06	4.32e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—CTNNB1—pancreatic cancer	6.54e-06	4.32e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—CTNNB1—pancreatic cancer	6.47e-06	4.28e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—TP53—pancreatic cancer	6.47e-06	4.27e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—MMP9—pancreatic cancer	6.46e-06	4.27e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—MMP9—pancreatic cancer	6.43e-06	4.25e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—PTEN—pancreatic cancer	6.43e-06	4.25e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—PIK3CB—pancreatic cancer	6.42e-06	4.24e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—PIK3CD—pancreatic cancer	6.42e-06	4.24e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—MMP9—pancreatic cancer	6.41e-06	4.23e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—PIK3CA—pancreatic cancer	6.4e-06	4.23e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—PTEN—pancreatic cancer	6.39e-06	4.22e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—PTEN—pancreatic cancer	6.37e-06	4.21e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—PTGS2—pancreatic cancer	6.36e-06	4.2e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—MMP9—pancreatic cancer	6.35e-06	4.19e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—PTEN—pancreatic cancer	6.31e-06	4.17e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—AKT1—pancreatic cancer	6.27e-06	4.14e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—AKT1—pancreatic cancer	6.23e-06	4.12e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—AKT1—pancreatic cancer	6.21e-06	4.11e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—TP53—pancreatic cancer	6.19e-06	4.09e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—HRAS—pancreatic cancer	6.19e-06	4.09e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—AKT1—pancreatic cancer	6.15e-06	4.07e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—PIK3CD—pancreatic cancer	6.05e-06	4e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—PIK3CD—pancreatic cancer	6e-06	3.96e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—SRC—pancreatic cancer	5.96e-06	3.94e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—SRC—pancreatic cancer	5.93e-06	3.92e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—HRAS—pancreatic cancer	5.92e-06	3.91e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—SRC—pancreatic cancer	5.91e-06	3.9e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—SRC—pancreatic cancer	5.85e-06	3.87e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—VEGFA—pancreatic cancer	5.8e-06	3.83e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—VEGFA—pancreatic cancer	5.77e-06	3.81e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—VEGFA—pancreatic cancer	5.75e-06	3.8e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—STAT3—pancreatic cancer	5.75e-06	3.8e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—NRAS—pancreatic cancer	5.73e-06	3.79e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—STAT3—pancreatic cancer	5.72e-06	3.78e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—NRAS—pancreatic cancer	5.7e-06	3.77e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—VEGFA—pancreatic cancer	5.7e-06	3.76e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—STAT3—pancreatic cancer	5.7e-06	3.76e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—NRAS—pancreatic cancer	5.68e-06	3.76e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—STAT3—pancreatic cancer	5.64e-06	3.73e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—NRAS—pancreatic cancer	5.63e-06	3.72e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—PIK3CB—pancreatic cancer	5.59e-06	3.7e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—PTEN—pancreatic cancer	5.55e-06	3.67e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—PTGS2—pancreatic cancer	5.54e-06	3.66e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—AKT1—pancreatic cancer	5.46e-06	3.61e-05	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—PIK3CA—pancreatic cancer	5.37e-06	3.55e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—MYC—pancreatic cancer	5.34e-06	3.53e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—TGFB1—pancreatic cancer	5.33e-06	3.52e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—MYC—pancreatic cancer	5.31e-06	3.51e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—TGFB1—pancreatic cancer	5.3e-06	3.5e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—MYC—pancreatic cancer	5.29e-06	3.5e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—TGFB1—pancreatic cancer	5.28e-06	3.49e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—PIK3CB—pancreatic cancer	5.27e-06	3.48e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—MYC—pancreatic cancer	5.24e-06	3.46e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—AKT1—pancreatic cancer	5.23e-06	3.46e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—TGFB1—pancreatic cancer	5.23e-06	3.46e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—PIK3CB—pancreatic cancer	5.23e-06	3.45e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—PTGS2—pancreatic cancer	5.22e-06	3.45e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—EGFR—pancreatic cancer	5.22e-06	3.45e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—EGFR—pancreatic cancer	5.19e-06	3.43e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—PTGS2—pancreatic cancer	5.18e-06	3.42e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—EGFR—pancreatic cancer	5.18e-06	3.42e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—EGFR—pancreatic cancer	5.13e-06	3.39e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—KRAS—pancreatic cancer	4.93e-06	3.26e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—KRAS—pancreatic cancer	4.91e-06	3.24e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—KRAS—pancreatic cancer	4.89e-06	3.23e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—KRAS—pancreatic cancer	4.84e-06	3.2e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—PTEN—pancreatic cancer	4.83e-06	3.19e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—PIK3CA—pancreatic cancer	4.62e-06	3.05e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—PTEN—pancreatic cancer	4.56e-06	3.01e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—PIK3CA—pancreatic cancer	4.53e-06	2.99e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—PTEN—pancreatic cancer	4.52e-06	2.98e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—PIK3CA—pancreatic cancer	4.51e-06	2.98e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—PIK3CA—pancreatic cancer	4.49e-06	2.97e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—PIK3CA—pancreatic cancer	4.45e-06	2.94e-05	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—AKT1—pancreatic cancer	4.39e-06	2.9e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—TP53—pancreatic cancer	4.39e-06	2.9e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—TP53—pancreatic cancer	4.36e-06	2.88e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—TP53—pancreatic cancer	4.35e-06	2.87e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—TP53—pancreatic cancer	4.31e-06	2.84e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—HRAS—pancreatic cancer	4.19e-06	2.77e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—HRAS—pancreatic cancer	4.17e-06	2.76e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—HRAS—pancreatic cancer	4.16e-06	2.75e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—HRAS—pancreatic cancer	4.12e-06	2.72e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—PIK3CA—pancreatic cancer	3.91e-06	2.59e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—AKT1—pancreatic cancer	3.78e-06	2.5e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—AKT1—pancreatic cancer	3.7e-06	2.45e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—AKT1—pancreatic cancer	3.68e-06	2.43e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—AKT1—pancreatic cancer	3.67e-06	2.43e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—AKT1—pancreatic cancer	3.64e-06	2.4e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—PIK3CA—pancreatic cancer	3.41e-06	2.25e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—PIK3CA—pancreatic cancer	3.21e-06	2.12e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—AKT1—pancreatic cancer	3.2e-06	2.11e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—PIK3CA—pancreatic cancer	3.19e-06	2.1e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—AKT1—pancreatic cancer	2.79e-06	1.84e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—AKT1—pancreatic cancer	2.63e-06	1.73e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—AKT1—pancreatic cancer	2.6e-06	1.72e-05	CbGpPWpGaD
